TWi Biotechnology Exploring Promising Treatment for Granuloma Annulare (GA)
- Written by PR Newswire
Company and Yale University Hospital seeking participants with GA for Phase 1 trials of medicine FDA-approved for other ailments
NEW HAVEN, Conn., June 2, 2023 /PRNewswire/ -- TWi Biotechnology (TWiB), a clinical stage biopharmaceutical company specializing in development of repositioned drugs for unmet medical needs, is currently seeking...













